NCT00000832View on ClinicalTrials.gov

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 1998

Conditions
HIV Infections
Interventions
BIOLOGICAL

MF59

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (4)

14642

Univ. of Rochester AVEG, Rochester

35294

UAB AVEG, Birmingham

63104

St. Louis Univ. School of Medicine AVEG, St Louis

Unknown

JHU AVEG, Pittsburgh

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000832 - A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers | Biotech Hunter | Biotech Hunter